Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

bsequent 12-week study period.

Anthony A. DiTonno, President and CEO, commented, "I am very pleased with our ability to complete the enrollment of this study ahead of plan. When we completed our initial public offering earlier this year, we indicated that we would file a new drug application (NDA) with the Food and Drug Administration (FDA) in the second half of 2008. Completion of enrollment in this study, on top of our three already completed successful Phase 3 trials, increases our confidence that we can meet this goal."

NeurogesX has successfully completed two Phase 3 studies in postherpetic neuralgia (PHN) and one in HIV-DSP. NGX-4010 has been granted orphan status and has received fast track designation from the FDA for HIV-DSP. NeurogesX believes that it is on track to file for marketing approval in the European Union before the end of 2007 for a broad indication of peripheral neuropathic pain. The Company is currently evaluating various regulatory filing strategies in the United States in order to most efficiently seek FDA approval of both the PHN and HIV-DSP indications, and believes that it will be able to submit a new drug application with the FDA in 2008.

About PHN and HIV-DSP

PHN is a painful condition affecting sensory nerve fibers. It is a complication of shingles, a second outbreak of the varicella-zoster virus, which initially causes chickenpox. Following an initial infection, some of the virus can remain dormant in nerve cells. Years later, age, illness, stress, medications or other factors that are not well understood can lead to reactivation of the virus. The rash and blisters associated with shingles usually heal within six weeks, but some people continue to experience pain for years thereafter. This pain is known as postherpetic neuralgia. PHN may occur in almost any area, but is especially common on the torso.

HIV-DSP is caused primarily by three factors: direct activation of cells known as sensory neurons by the
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage ... regeneration, today announced that J.J. Finkelstein , chief ... corporate overview at two upcoming investor conferences. ... th Annual Microcap Conference on Thursday May 28, ... at 11:00 am EDT.  A webcast will be available ...
(Date:5/22/2015)... According to a new market research report ... by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020", published by MarketsandMarkets, the global ... Million by 2020 from $452.36 Million in 2015, growing ... 71 market data Tables and 90 Figures spread through ...
(Date:5/22/2015)... 22, 2015  In a sweeping analysis assessing the ... T1D Exchange researchers conclude that there remains considerable ... across all age groups, but especially for adolescents and ... of diabetes treatment, underscoring the need to address barriers ... can help type 1 patients achieve optimal metabolic control. ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... , PRINCETON, N.J. and SAN DIEGO, ... biotechnology company committed to research and product discovery for ... announced results from an in vitro study evaluating TBR-652 ... tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the ...
... PARIS and TARRYTOWN, N.Y., Sept. 11 Sanofi-aventis ... Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced the ... Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line ... by an Independent Data Monitoring Committee (IDMC). As part ...
Cached Medicine Technology:Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 3Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 5
(Date:5/22/2015)... (PRWEB) May 22, 2015 In April ... In the past 9 years they have concentrated their ... United States and Canada. Because of this growth and ... established corporate offices in Denver, Colorado, Cleveland, Ohio, Houston, ... specializes in opening new dental offices, dental start ups, ...
(Date:5/22/2015)... A new program for the "In America" television series ... Therapy. , James Earl Jones will host the ... therapy and discusses how the exercises can decrease pain ... ailments and injuries. Physical therapists work with their ... daily activities such as house cleaning and shopping, work ...
(Date:5/22/2015)... Maine (PRWEB) May 22, 2015 ... single-use swabs for the medical, diagnostic, environmental, and ... entire line of products in the US. At ... their operations outside the US, Puritan remains committed ... products at their Guilford, Maine facility. , Since ...
(Date:5/22/2015)... May 22, 2015 Yisrayl Hawkins, Pastor and ... released a new letter calling on religious leaders to make ... which was published on his blog, discusses the history of ... needed to stop it. Yisrayl says mankind was created to ... experienced in today’s society. , “Yahweh created mankind, according ...
(Date:5/22/2015)... May 22, 2015 Pro3rd Impression ... designed exclusively for Final Cut Pro X. Pro3rd Impression's ... design. , Intuitive on-screen-controls allow users to customize ... Reflections, colors, layouts, and much more can be edited ... , Pro3rd Impression comes packed with 30 ...
Breaking Medicine News(10 mins):Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:Developers at Pixel Film Studios Release Pro3rd Impression for Final Cut Pro X. 2
... shown that it seems to stop mice with the ... such vaccines could delay or prevent similar symptoms in ... deposits in mouse brains -the other major indicator of ... Ireland, is poised to begin human clinical trails of ...
... to test the importance of sleep for memory and ... effects, such as fatigue and reduced alertness. ... complications by allowing recovery sleep by Harvard Medical school ... day showed no improvement in task performance but those ...
... were 16 years old and the men were 13.5 years ... ,It appears that the sexual abuse or assault was ... thyroid diseases. It varied by gender, where arthritis and breast ... occur in men. ,There is an association between ...
... be remembered as one of the most controversial presidents ever. ... history to be impeached by the House of Representatives. Only ... save himself and his country further damage. ,He has ... and his mid east peace efforts have always come unstuck ...
... concluded Indian science congress in New Delhi have called for ... iron fortification of crops. Almost 50% of women and 75% ... While iron supplementation is expensive, fortification of plants with iron ... is fairly cheaper, scientists say. ,This idea has found ...
... scientists revealed that two antioxidants in black pepper and ... the bacterial DNA from damage by irradiation in test ... effect and protecting organisms like Escherichia role and Bacillus ... ,The study offers hope for the development of ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: